Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development
- 1 September 2018
- journal article
- research article
- Published by Elsevier in New Biotechnology
- Vol. 44, 31-40
Abstract
No abstract availableKeywords
Funding Information
- Acticor Biotech
This publication has 39 references indexed in Scilit:
- Recombinant antibodies: Engineering and production in yeast and bacterial hostsBiotechnology Journal, 2010
- Directed evolution of a secretory leader for the improved expression of heterologous proteins and full‐length antibodies in Saccharomyces cerevisiaeBiotechnology and Bioengineering, 2009
- Development trends for therapeutic antibody fragmentsNature Biotechnology, 2009
- Process economics of industrial monoclonal antibody manufactureJournal of Chromatography B, 2007
- Is any measurement method optimal for all aggregate sizes and types?The AAPS Journal, 2006
- Manufacturing of recombinant therapeutic proteins in microbial systemsBiotechnology Journal, 2006
- Expression of heterologous proteins inPichia pastoris: a useful experimental tool in protein engineering and productionJournal of Molecular Recognition, 2004
- In Vivo Synthesis of Mammalian-Like, Hybrid-Type N-Glycans inPichia pastorisApplied and Environmental Microbiology, 2004
- A new generation of information retrieval tools for biologists: the example of the ExPASy WWW serverTrends in Biochemical Sciences, 1994
- Recent Advances in the Expression of Foreign Genes in Pichia pastorisNature Biotechnology, 1993